Mr. R. Matt Davis's most recent trade in Altria Group Inc. was a trade of 2,571 Common Stock done . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altria Group | Mr. R. Matt Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 2,571 | 18,063 (0%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Mr. Matthew W. Davis, R.Ph. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2026 | 50,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Mr. Matthew W. Davis, R.Ph. | Chief Development Officer | 09 Mar 2026 | 50,000 | 50,000 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Altria Group | Mr. R. Matt Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 3,219 | 15,492 (0%) | 0% | 0 | Common Stock | |
| Altria Group | Mr. R. Matt Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 3,800 | 12,273 (0%) | 0% | 0 | Common Stock | |
| Altria Group | Mr. R. Matt Davis | Director | Purchase of securities on an exchange or from another person at price $ 40.50 per share. | 06 Nov 2023 | 1,200 | 8,473 (0%) | 0% | 40.5 | 48,599 | Common Stock |
| Altria Group | Mr. R. Matt Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,901 | 7,273 (0%) | 0% | 0 | Common Stock | |
| Altria Group | Mr. R. Matt Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 3,372 | 3,372 (0%) | 0% | 0 | Common Stock |